A Randomised, Open-Label, Multi-Centre Phase II Study of BAY 43-9006 ( Sorafenib) Versus Standard Treatment With Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 01 Jan 2014
At a glance
- Drugs Sorafenib (Primary) ; Interferon alpha-2a
- Indications Renal cancer
- Focus Therapeutic Use
- Sponsors Bayer
- 02 Feb 2009 Status changed from active, no longer recruiting to completed.
- 26 Jan 2009 Results were published in the Journal of Clinical Oncology in Jan 2009.
- 28 Sep 2008 Planned end date changed from 1 Mar 2008 to 1 Apr 2009 according to the ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History